(WSJ) – The Danish drugmaker would take the lead in developing, manufacturing and commercializing any new drugs resulting from the deal

Novo Nordisk struck a licensing deal valued at up to $2.1 billion to gain access to oral drug-delivery technologies developed by U.S. startup Vivtex, as the Danish drugmaker moves to deepen its pipeline of next-generation obesity medicines. (Read More)